Reference is made to the private placement (the "Private Placement") announced by Oncoinvent ASA on 22 September 2026. Please see the attached PDMR-forms for primary insiders and close associates related to allocation of shares in the Private Placement.
PDMR attachement 22.09.2026.pdf
This information is published in accordance with article 19 of the EU Market Abuse Regulation (MAR).
For further information, please contact:
Oystein Soug, Chief Executive Officer
Email: IR@oncoinvent.com
https://news.cision.com/oncoinvent-asa/r/oncoinvent-asa---mandatory-notification-of-trade,c4399514
https://mb.cision.com/Public/15728/4399514/956a83e81964cc9f.pdf
(c) 2026 Cision. All rights reserved., source Press Releases - English